These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16798005)

  • 1. Cromolyn administration (to block mast cell degranulation) reduces necrosis of dystrophic muscle in mdx mice.
    Radley HG; Grounds MD
    Neurobiol Dis; 2006 Aug; 23(2):387-97. PubMed ID: 16798005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment.
    Radley HG; Davies MJ; Grounds MD
    Neuromuscul Disord; 2008 Mar; 18(3):227-38. PubMed ID: 18207402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice.
    Hodgetts S; Radley H; Davies M; Grounds MD
    Neuromuscul Disord; 2006 Oct; 16(9-10):591-602. PubMed ID: 16935507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disodium cromoglycate protects dystrophin-deficient muscle fibers from leakiness.
    Marques MJ; Ventura Machado R; Minatel E; Santo Neto H
    Muscle Nerve; 2008 Jan; 37(1):61-7. PubMed ID: 17724738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors inducing mast cell accumulation in skeletal muscle.
    Lefaucheur JP; Gjata B; Sebille A
    Neuropathol Appl Neurobiol; 1996 Jun; 22(3):248-55. PubMed ID: 8804027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of TNF in vivo using cV1q antibody reduces contractile dysfunction of skeletal muscle in response to eccentric exercise in dystrophic mdx and normal mice.
    Piers AT; Lavin T; Radley-Crabb HG; Bakker AJ; Grounds MD; Pinniger GJ
    Neuromuscul Disord; 2011 Feb; 21(2):132-41. PubMed ID: 21055937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of cross-talk between tumour necrosis factor and insulin-like growth factor-1 signalling in skeletal muscle.
    Grounds MD; Radley HG; Gebski BL; Bogoyevitch MA; Shavlakadze T
    Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):846-51. PubMed ID: 18215180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice.
    Messina S; Bitto A; Aguennouz M; Minutoli L; Monici MC; Altavilla D; Squadrito F; Vita G
    Exp Neurol; 2006 Mar; 198(1):234-41. PubMed ID: 16410003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice.
    Schertzer JD; Ryall JG; Lynch GS
    Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E499-505. PubMed ID: 16621899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single 30 min treadmill exercise session is suitable for 'proof-of concept studies' in adult mdx mice: a comparison of the early consequences of two different treadmill protocols.
    Radley-Crabb H; Terrill J; Shavlakadze T; Tonkin J; Arthur P; Grounds M
    Neuromuscul Disord; 2012 Feb; 22(2):170-82. PubMed ID: 21835619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis.
    Grounds MD; Torrisi J
    FASEB J; 2004 Apr; 18(6):676-82. PubMed ID: 15054089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced sensitivity of mdx mice to intramuscular injection of compound 48/80.
    Granchelli JA; Hudecki MS; Pollina CM
    Res Commun Chem Pathol Pharmacol; 1994 Jun; 84(3):351-62. PubMed ID: 7938907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse.
    Briguet A; Courdier-Fruh I; Foster M; Meier T; Magyar JP
    Neuromuscul Disord; 2004 Oct; 14(10):675-82. PubMed ID: 15351425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myonuclear apoptosis in dystrophic mdx muscle occurs by perforin-mediated cytotoxicity.
    Spencer MJ; Walsh CM; Dorshkind KA; Rodriguez EM; Tidball JG
    J Clin Invest; 1997 Jun; 99(11):2745-51. PubMed ID: 9169505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species.
    Whitehead NP; Yeung EW; Allen DG
    Clin Exp Pharmacol Physiol; 2006 Jul; 33(7):657-62. PubMed ID: 16789936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx mice.
    Shavlakadze T; White J; Hoh JF; Rosenthal N; Grounds MD
    Mol Ther; 2004 Nov; 10(5):829-43. PubMed ID: 15509501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of deltaCaMKII isoforms in skeletal muscle regeneration: Implications in dystrophic muscle disease.
    Abraham ST; Shaw C
    J Cell Biochem; 2006 Feb; 97(3):621-32. PubMed ID: 16215994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muscle genome-wide expression profiling during disease evolution in mdx mice.
    Marotta M; Ruiz-Roig C; Sarria Y; Peiro JL; Nuñez F; Ceron J; Munell F; Roig-Quilis M
    Physiol Genomics; 2009 Apr; 37(2):119-32. PubMed ID: 19223608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strength and corticosteroid responsiveness of mdx mice is unchanged by RAG2 gene knockout.
    Golumbek PT; Keeling RM; Connolly AM
    Neuromuscul Disord; 2007 May; 17(5):376-84. PubMed ID: 17452104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T and B lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid/mdx mouse.
    Farini A; Meregalli M; Belicchi M; Battistelli M; Parolini D; D'Antona G; Gavina M; Ottoboni L; Constantin G; Bottinelli R; Torrente Y
    J Pathol; 2007 Oct; 213(2):229-38. PubMed ID: 17668421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.